Envoy Medical (NASDAQ:COCH) Shares Down 0.3% – Time to Sell?

Envoy Medical, Inc. (NASDAQ:COCH)’s share price fell 0.3% on Monday . The stock traded as low as $0.4585 and last traded at $0.4701. 196,708 shares were traded during trading, an increase of 31% from the average session volume of 150,372 shares. The stock had previously closed at $0.4715.

Analyst Ratings Changes

COCH has been the subject of a number of analyst reports. Wall Street Zen raised Envoy Medical to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a research note on Tuesday, January 27th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Envoy Medical presently has a consensus rating of “Hold” and a consensus price target of $9.50.

Envoy Medical Price Performance

The company has a fifty day moving average of $0.70 and a two-hundred day moving average of $0.93. The stock has a market capitalization of $13.53 million, a P/E ratio of -0.33 and a beta of 2.10.

Envoy Medical (NASDAQ:COCH) last issued its earnings results on Monday, November 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.08). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.05 million. As a group, equities research analysts predict that Envoy Medical, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Trading of Envoy Medical

Institutional investors have recently added to or reduced their stakes in the business. Focus Partners Wealth acquired a new stake in shares of Envoy Medical during the first quarter worth $276,000. NorthRock Partners LLC bought a new stake in shares of Envoy Medical during the 2nd quarter valued at about $14,612,000. CIBC Bancorp USA Inc. acquired a new stake in Envoy Medical during the third quarter worth about $60,000. Finally, Geode Capital Management LLC raised its stake in Envoy Medical by 111.3% during the fourth quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after acquiring an additional 51,813 shares during the period. Institutional investors own 8.59% of the company’s stock.

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.